Hi
@Pixie
As requested, a brief reflection on today's AGM are below.
All resolutions passed.
Travelan, in GP dollars I was impressed to learn that this asset is giving IMC $700k a year profit (vs aprox just $50k of profit a year a few years ago). Thumbs up from me, this is $700k a year (and growing) that IMC doesn't have to go and raise from the market. And, it's on the pharmacy shelves, it has a presence and it's doing its thing with minimal effort/investment needed.
The same can be said for Protectyn, but it's early days there and at this stage is only available via naturopaths/practitioners and is being managed by someone specifically appointed to manage that channel.
Will they throw more money at marketing these OTC products? Management were unanimous that the answer is NO. All hands are on the NASH deck- this is the big ticket item that will deliver the most value for shareholders in the short term and to invest effort and capital on inferior opportunities would not be fair to shareholders... Tobira was taken over for US$1.7b... after their product FAILED its phase II NASH trial!
So what's IMC worth if they deliver a successful phase II trial? We will find out Q1 next year. Recruitment is just about complete and will be done by first week of Jan at the latest.
The decision was made to deliver the interim results from the NASH trial Q1 next year vs the current quarter as the sample size will be larger and more statistically significant. Big pharma will look at the results more seriously.
Management advised that there will be a substantial increase in time and capital invested in promoting this company as the company is entering a phase now where there will be more newsflow and critical inflection points. They want IMC to be on everyone's radar at this juncture.
I thought there was a real sense of purpose amongst management, they are all on the same page, focused, and determined to make Immuron a success story.
The next 3 months will be massive. I left the AGM feeling very confident.
